Massachusetts Institute of Technology
|Postdoctoral Associate
US
→
Yuang Chen
About
Work
Education
University of Pittsburgh
United States of America
→
Ph.D.
Publications
The lncRNA EPIC1 suppresses dsRNA-induced type I IFN signaling and is a therapeutic target to enhance TNBC response to PD-1 inhibition
Science Signaling
journal-article
The lncRNA EPIC1 suppresses dsRNA-induced type I IFN signaling and is a therapeutic target to enhance TNBC response to PD-1 inhibition
Science Signaling
journal-article
Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance
Nature Communications
journal-article
Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy
Nature Communications
journal-article
Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy
Nature Nanotechnology
journal-article
Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response
Science Advances
journal-article
Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages
Acta Pharmaceutica Sinica B
journal-article
Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination.
Molecular therapy. Nucleic acids
journal-article